Elizabeth Yeu Lin Sells 5,387 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Lin sold 5,387 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $80.00, for a total value of $430,960.00. Following the completion of the sale, the insider directly owned 13,320 shares in the company, valued at $1,065,600. This represents a 28.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total transaction of $127,200.00.
• On Tuesday, September 1st, Elizabeth Lin sold 4,601 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $73.86, for a total transaction of $339,829.86.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $90.78 on Friday. The company has a 50-day moving average price of $66.01 and a two-hundred day moving average price of $65.93. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of -83.28 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The business had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TARS. HC Wainwright restated a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Mizuho lowered their target price on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Friday, July 17th. Guggenheim reduced their price target on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Tuesday, July 21st. Finally, Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.50.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus completed its acquisition of Alkeus, obtaining worldwide rights to gildeuretinol (ALK-001), an investigational once-daily oral treatment for Stargardt disease. The rare inherited eye disease has no FDA-approved therapy and may affect up to 86,000 people in the United States. Tarsus completes Alkeus acquisition
• Positive Sentiment: ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial and has received FDA Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations. The regulatory designations and potential to address a significant unmet need strengthen Tarsus’ pipeline, although topline trial data are not expected until 2029. Alkeus acquisition adds Phase 3 program
• Positive Sentiment: Newly published TEASE-1 results showed that daily gildeuretinol significantly reduced the growth rate of retinal atrophic lesions versus an untreated group and was well tolerated, with no reported delays in dark adaptation or night blindness. TEASE-1 study results
• Neutral Sentiment: The acquisition expands Tarsus beyond its commercial XDEMVY business and supports management’s strategy of building a broader eye-care company. However, the transaction’s financial terms and the ultimate commercial value of ALK-001 were not detailed in the reports.
• Negative Sentiment: Insider Elizabeth Lin reported multiple sales totaling approximately $898,000 across September 1–2 under a pre-arranged Rule 10b5-1 trading plan. While such planned transactions may not reflect current management views, the sales add a modest cautionary signal for investors.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. grew its holdings in Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after acquiring an additional 172 shares during the period. Parallel Advisors LLC lifted its holdings in Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after acquiring an additional 291 shares during the last quarter. State of Wisconsin Investment Board lifted its holdings in Tarsus Pharmaceuticals by 1.1% in the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after acquiring an additional 332 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after purchasing an additional 339 shares in the last quarter. Finally, Valeo Financial Advisors LLC grew its stake in shares of Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after purchasing an additional 392 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.